In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vernalis (R&D) Ltd.

http://www.vernalis.com

Latest From Vernalis (R&D) Ltd.

Amryt Predicts $1bn Revenues After Chiasma Acquisition

The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.

M & A Rare Diseases

EU Accelerated Assessment Tracker

Calliditas Therapeutics' lead product candidate Nefecon will be fast-tracked at the EMA once the marketing application is filed. Takeda and Bayer are hoping for the same success with aribavir and copanlisib respectively.

Europe Review Pathway

Takeda’s CMV Infection ‘Game-Changer’ Among EU Fast-Track Hopefuls

Takeda, Calliditas and Bayer are set to learn whether the European Medicines Agency will grant their respective products accelerated assessment status when they file for pan-EU marketing approval.

Europe Review Pathway

Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers

Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Cita NeuroPharmaceuticals
    • Vernalis Group plc
UsernamePublicRestriction

Register